论文部分内容阅读
目的探讨阿托伐他汀序贯疗法对冠状动脉支架置入术后患者再狭窄和临床远期疗效的影响。方法将确诊冠心病并行支架置入术治疗的125例患者分为观察组和对照组;观察组术前阿托伐他汀80 mg顿服,术后改40 mg/次,1次/d,30 d后再改为20 mg/次,1次/d;对照组维持20 mg/次,1次/d。观察治疗后6个月血脂、管腔造影情况、心血管事件发生率等指标的变化。结果观察组LDL、HDL、最小管腔直径和狭窄百分比等指标与对照组相比有明显改善,差异有统计学意义(P<0.05)。观察组心血管事件的发生率明显少于对照组(P<0.05)。结论阿托伐他汀序贯疗法能够有效地减少支架置入术后再狭窄,降低术后心血管事件的发生率,改善患者预后。
Objective To investigate the effect of sequential atorvastatin on patients with restenosis and clinical long-term effect after coronary stent implantation. Methods One hundred and twenty-five patients with confirmed coronary heart disease (CAD) treated with stenting were divided into observation group and control group. The observation group received atorvastatin 80 mg daily before operation and 40 mg / time, once / d, 30 d and then changed to 20 mg / time, 1 / d; control group to maintain 20 mg / time, 1 / d. Observed at 6 months after treatment lipids, luminal angiography, cardiovascular events and other indicators of change. Results The indexes of LDL, HDL, the smallest lumen diameter and the percentage of stenosis in the observation group were significantly improved compared with the control group, the difference was statistically significant (P <0.05). The incidence of cardiovascular events in the observation group was significantly less than that in the control group (P <0.05). Conclusions Atorvastatin sequential therapy can effectively reduce the restenosis after stenting, reduce the incidence of postoperative cardiovascular events and improve the prognosis of patients.